学术探索
学术期刊
新闻热点
数据分析
智能评审

2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: Clinical practice guidelines of the American Society of Clinical Oncology

被引：170
作者：
Schuchter, LM [1 ]
Hensley, ML [1 ]
Meropol, NJ [1 ]
Winer, EP [1 ]
机构：
[1] Amer Soc Clin Oncol, Alexandria, VA 22314 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2002年 / 20卷 / 12期
关键词：
D O I：
10.1200/JCO.2002.04.178
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：2895 / 2903
页数：9
相关论文
共 28 条
  • [1] COMPARATIVE-STUDY OF THE PHARMACOKINETICS AND TOXICITY OF HIGH-DOSE EPIRUBICIN WITH OR WITHOUT DEXRAZOXANE IN PATIENTS WITH ADVANCED MALIGNANCY
    BASSER, RL
    SOBOL, MM
    DUGGAN, G
    CEBON, J
    ROSENTHAL, MA
    MIHALY, G
    GREEN, MD
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (08) : 1659 - 1666
  • [2] Epirubicin-based chemotherapy in metastatic breast cancer patients:: Role of dose-intensity and duration of treatment
    Bastit, P
    Chevallier, B
    Chevreau, C
    Mihura, J
    Roché, H
    Namer, M
    Gédouin, D
    Kerbrat, P
    Lesimple, T
    Coudert, B
    Fargeot, P
    de Gislain, C
    Mayer, F
    Luporsi, E
    Rios, M
    Weber, B
    Brémond, A
    Devaux, Y
    Monteuquet, P
    Schraub, S
    Hayat, M
    Zambon, E
    Grandgirard, A
    Monnier, A
    Sun, X
    Clavère, P
    Ollivier, JP
    Rhein, B
    Roullet, B
    Chollet, P
    Van Praagh, I
    Cattan, A
    Eymard, JC
    Pourny, C
    Facchini, T
    Walter, S
    Dides, S
    Ramos, R
    Guiochet, N
    Seffert, P
    Perpoint, X
    Sztermer, JF
    Cretin, J
    Goudier, MJ
    Morice, F
    Delecroix, V
    Fumoleau, P
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (17) : 3115 - 3124
  • [3] A pharmacoeconomic evaluation of the use of dexrazoxane in preventing anthracycline-induced cardiotoxicity in patients with stage IIIB or IV metastatic breast cancer
    Bates, M
    Lieu, D
    Zagari, M
    Spiers, A
    Williamson, T
    [J]. CLINICAL THERAPEUTICS, 1997, 19 (01) : 167 - 184
  • [4] Salivary gland protection by amifostine in high-dose radioiodine treatment: Results of a double-blind placebo-controlled study
    Bohuslavizki, KH
    Klutmann, S
    Brenner, W
    Mester, J
    Henze, E
    Clausen, M
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (11) : 3542 - 3549
  • [5] A randomized study of very accelerated radiotherapy with and without amifostine in head and neck squamous cell carcinoma
    Bourhis, J
    De Crevoisier, R
    Abdulkarim, B
    Deutsch, E
    Lusinchi, A
    Luboinski, B
    Wibault, P
    Eschwege, F
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2000, 46 (05): : 1105 - 1108
  • [6] Phase III randomized trial of amifostine as a radioprotector in head and neck cancer
    Brizel, DM
    Wasserman, TH
    Henke, M
    Strnad, V
    Rudat, V
    Monnier, A
    Eschwege, F
    Zhang, J
    Russell, L
    Oster, W
    Sauer, R
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (19) : 3339 - 3345
  • [7] Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer
    Buntzel, J
    Kuttner, K
    Frohlich, D
    Glatzel, M
    [J]. ANNALS OF ONCOLOGY, 1998, 9 (05) : 505 - 509
  • [8] A randomised multicentre trial of CHART versus conventional radiotherapy in head and neck cancer
    Dische, S
    Saunders, M
    Barrett, A
    Harvey, A
    Gibson, D
    Parmar, M
    [J]. RADIOTHERAPY AND ONCOLOGY, 1997, 44 (02) : 123 - 136
  • [9] FELDMAN SE, 1992, P AN M AM SOC CLIN, V11, P296
  • [10] Randomized phase II study of high-dose paclitaxel with or without amifostine in patients with metastatic breast cancer
    Gelmon, K
    Eisenhauer, E
    Bryce, C
    Tolcher, A
    Mayer, L
    Tomlinson, E
    Zee, B
    Blackstein, M
    Tomiak, E
    Yau, J
    Batist, G
    Fisher, B
    Iglesias, J
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (10) : 3038 - 3047
123